IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failure.According to current guideline recommendations, there are limited indications for non-steroidal MRAs. Therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted.
Primary IgA nephropathy (IgAN) is an immunopathological diagnostic term for a type of glomerulonephritis characterised by the deposition of IgA or IgA-dominant immune complexes in the glomerular tunica albuginea. And in China IgA nephropathy accounts for about 45% of primary glomerular diseases and about 26% of renal biopsies in patients with chronic failure. Among them, about 15-40% of IgA nephropathy patients progress to renal failure after 10-20 years; IgA nephropathy has become one of the main causes of end-stage renal failure.The nonsteroidal salicorticoid receptor antagonist (MRA)- finerenone reduces the risk of composite renal outcomes, ESKD, or renal death in patients with type 2 diabetes and CKD.There are limited indications for non-steroidal MRAs. Therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted.
Study Type
OBSERVATIONAL
Enrollment
245
Taking the maximum tolerated dose of finerenone based on serum creatinine and blood potassium levels
Receive RAS inhibitor treatment as specified in the KDIGO guidelines
Receive immune suppressant treatment as specified in the KDIGO guidelines
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy
Yiwu, Zhejiang, China
percentage change in PCR from baseline to 6 months
Collect PCR data before enrolment and at month 6 and calculate the percentage change
Time frame: 6 month
percentage change in PCR from baseline to 1, 2 and 3 months
Collec PCR before enrolment and at months 1, 2 and 3, then calculate the percentage change
Time frame: 1, 2 and 3 month
frequency of patients with a 30% and 50% decrease in PCR
Calculate the number of patients with \>30% or \>50% reduction in proteinuria during the 6-month follow-up period
Time frame: 6 month
the level of change in eGFR
Collection of eGFR before enrolment and at months 6
Time frame: 6 month
the level of change in blood sodium
Collection of blood sodium before enrolment and at months 6
Time frame: 6 month
the level of change in serum creatinine
Collection of serum creatinine before enrolment and at months 6
Time frame: 6 month
the level of change in albumin
Collection of albumin before enrolment and at months 6
Time frame: 6 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.